Navidea Financial Statements From 2010 to 2026
| NAVB Stock | USD 0.0001 0.00 0.00% |
Check Navidea Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Navidea Biopharmaceutica's main balance sheet or income statement drivers, such as , as well as many indicators such as . Navidea financial statements analysis is a perfect complement when working with Navidea Biopharmaceutica Valuation or Volatility modules.
Navidea |
Navidea Biopharmaceuticals Company Return On Equity Analysis
Navidea Biopharmaceutica's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Navidea Biopharmaceutica Return On Equity | -11.0 |
Most of Navidea Biopharmaceutica's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Navidea Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Navidea Biopharmaceuticals has a Return On Equity of -11.0012. This is 54.1% lower than that of the Biotechnology sector and 69.83% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Navidea Biopharmaceutica Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Navidea Biopharmaceutica's current stock value. Our valuation model uses many indicators to compare Navidea Biopharmaceutica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Navidea Biopharmaceutica competition to find correlations between indicators driving Navidea Biopharmaceutica's intrinsic value. More Info.Navidea Biopharmaceuticals is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Navidea Biopharmaceutica by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Navidea Biopharmaceutica's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Navidea Biopharmaceutica Financial Statements
Navidea Biopharmaceutica stakeholders use historical fundamental indicators, such as Navidea Biopharmaceutica's revenue or net income, to determine how well the company is positioned to perform in the future. Although Navidea Biopharmaceutica investors may analyze each financial statement separately, they are all interrelated. For example, changes in Navidea Biopharmaceutica's assets and liabilities are reflected in the revenues and expenses on Navidea Biopharmaceutica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Navidea Biopharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. Navidea Biopharmaceutica operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 11 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Navidea Pink Sheet
When determining whether Navidea Biopharmaceutica is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Navidea Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Navidea Biopharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Navidea Biopharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.